Delvys R. A.
- Country
- Spain
- Department
- Servicio de Oncología Médica
Research Overview
- Phase I Evaluation of FS222 for Safety and Efficacy in Patients with Advanced Malignancies
- Phase 1 Study of CLN-619 Alone or with Pembrolizumab in Advanced Solid Tumors, Including NSCLC, Cervical, Endometrial, Ovarian, Breast, and Gastrointestinal Cancers
- Efficacy of Cobolimab, Dostarlimab, and Docetaxel in Advanced Non-Small Cell Lung Cancer Post Anti-PD(L)1 Therapy and Chemotherapy
Data & Insights
Has run more than one trial at 460 of 750 partner sites.
Specializations
Thoracic oncology
Clinical research activity is strongly centered on non-small cell lung cancer and small cell lung cancer, with attention to advanced, metastatic, resectable, and biomarker-defined disease. The portfolio also includes lung cancer subtypes linked to EGFR, ALK, RET, KRAS G12C, and MET alterations.
- Advanced non-small cell lung cancer
- Extensive-stage and limited-stage small cell lung cancer
- Targeted therapy in oncogene-driven lung cancer
Interest extends to perioperative and metastatic treatment strategies for thoracic malignancies, including studies in PD-L1-selected populations and disease with brain involvement.
Breast cancer and hormone receptor–driven disease
The investigator is actively involved in trials across early breast cancer, metastatic breast cancer, and high-risk recurrent disease, especially HER2-positive, HER2-negative, and HR-positive subtypes. Research also includes tumors with PIK3CA, ESR1, BRCA, and homologous recombination repair alterations.
- HER2-directed treatment in early and advanced breast cancer
- Endocrine-based strategies in HR-positive disease
- Biomarker-selected metastatic breast cancer
Additional focus includes triple-negative breast cancer, isolated locoregional recurrence, and adjuvant approaches aimed at reducing relapse risk.
Hematologic malignancies
Research involvement covers a broad spectrum of blood cancers, including multiple myeloma, chronic lymphocytic leukemia, diffuse large B-cell lymphoma, Hodgkin lymphoma, and acute leukemia. The portfolio also includes light chain amyloidosis and other plasma cell disorders.
- Relapsed and refractory multiple myeloma
- Chronic lymphocytic leukemia and small lymphocytic lymphoma
- Lymphoma and plasma cell dyscrasias
Therapeutic interest extends to combination regimens, maintenance strategies, and treatment optimization in transplant-eligible and transplant-ineligible settings.
Genitourinary and gastrointestinal malignancies
The clinical trial landscape includes urothelial carcinoma, bladder cancer, renal cell carcinoma, prostate cancer, colorectal cancer, and gastrointestinal stromal tumor. Studies also span pancreatic cancer, ovarian cancer, and endometrial cancer.
- Advanced urothelial and bladder cancer
- Metastatic colorectal and pancreatic cancer
- Gynecologic malignancies
This area reflects a strong interest in biomarker-informed oncology and treatment approaches for advanced solid tumors with limited therapeutic options.
Immune-mediated, inflammatory, and cardiovascular disease
Beyond oncology, the investigator is involved in studies of systemic lupus erythematosus, Sjögren’s syndrome, psoriatic arthritis, idiopathic inflammatory myopathies, and uveitis. Cardiometabolic and vascular research includes atherosclerotic cardiovascular disease, spontaneous coronary artery dissection, obesity, and type 2 diabetes.
- Autoimmune and rheumatologic disorders
- Cardiovascular prevention and vascular disease
- Metabolic disease and obesity-related risk
Additional therapeutic interests include severe asthma, HIV infection, and selected renal and transplant-related conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.